Lyell Immunopharma, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Lyell Immunopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
  • Lyell Immunopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$44.6M, a 12.3% increase year-over-year.
  • Lyell Immunopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$204M, a 7.31% decline year-over-year.
  • Lyell Immunopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$235M, a 28.1% decline from 2022.
  • Lyell Immunopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$183M, a 26.8% increase from 2021.
  • Lyell Immunopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$250M, a 22.4% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$235M -$51.5M -28.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 -$183M +$67.1M +26.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 -$250M -$45.7M -22.4% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$204M -$75.1M -58% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$129M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.